HEALTHTECH COMPANY
TRANSFORMING STEM CELL THERAPY
TRANSFORMING STEM CELL THERAPY
without barriers to regenerative medicine
About Us
We are an early-stage healthtech company developing AI-powered cellular therapies for bone regeneration, born from the scientific and technological research of our founders
ADVANCED THERAPY MEDICAL PRODUCT | ALLOGENIC MESENCHYMAL STEM CELLS PLUS HYALURONIC ACID | EXTRACTION FROM UMBILICAL CORD | EX VIVO & SCALABLE PRODUCTION
Our Mission
To advance regenerative cell therapies for bone injuries, improving healing and quality of life without barriers.
Value Proposition
INTELLECTUAL PROPERTY
Argentina & PCT
Protocol Production
Ready to use solution without scaffold
Long Term Efficacy
Designed for lifelong effectiveness
Regulatory & Safety Prfile
Offering safety and efficacy
HYALURONIC ACID INNOVATION
Leveraging the Potential of Hyaluronic Acid
To advance regenerative cell
therapies for bone injuries
IMPROVING HEALING AND QUALITY OF LIFE WITHOUT BARRIERS
Timeline and Milestones, past and future
Next 2026
Expanded
FUTURE MILESTONES
- Finalization of Clinical Study Design
- First Patient Enrollment for Phase 1 Clinical Trial
- Complete Phase 1 Clinical Trial
- Development of Stem Cell Technology Platform
Next 2025
Expanded
REGULATORY APPROVALS
- Regulatory Approval and Market Entry Strategy
- Evaluation Request to ANMAT/INCUCAI for Clinical Application
October 24 - January 25
MVP Development
MVP DEVELOPMENT
- Signature of R&D agreement with CONICET - UNNOBA
- Signature of R&D agreement with Hosp. Garrahan
- Product development under GMP in Hosp. Garrahan
December 23 - July 24
Agreements with collaborators
Agreements with collaborators
- The Research Board of Hospital Garrahan approved the collaboration with the Cord Blood Bank
- Term Sheet for the License Agreement signed with CONICET and UNNOBA
January 21 - October 23
Startup Creation Process
Startup Creation Process
- Project Beginning
- Approval by the SF500 Investment Committee
- Registration Mesenchyal-T Inc
2021
Startup Creation Process
- Project Beginning
- Positive patentability evaluation by CONICET
02/2023
Startup Creation Process
- SF500 BUILD Selection and participation
06/2023
Startup Creation Process
- Patent aplication INPI
- SF500 Investment commitee approva
10/2023
Startup Creation Process
- Participation Regulatory. Assistance Prgogram AR R&D ANMAT
- S.A registration Mesenchyal-T S.A
12/2023
Fundraising Agreements with collaborators
- Aplication to EMPRETECNO 2023 (FONARSEC)
- «Acelerar España 2023»
06/2024
Fundraising Agreements with collaborators
- Patent Aplication PCT
- Reseach board Hosp Garrahan aprobe the colaboration with cord bank
07/2024
Fundraising Agreements with collaborators
- Signature of 75 license agreement CONICET – UNNOBA
- Trademark registration INPI
10/2024
Fundrasing MVP Development
- Signature of R&D agreement with CONICET – UNNOBA
- Signature of R&D agreement with Hosp. Garraham
2024/25
Fundrasing MVP Development
- Product development under GMP in Hosp. Garrhan
- Product development under GMP in Hosp. Garrhan
Next 2025
Regulatory approvals Internationalazation
- Signature of 75 license agreement CONICET – UNNOBA
- Trademark registration INPI
Next 2025
Regulatory approvals Internationalazation
- Signature of R&D agreement with CONICET – UNNOBA
- Signature of R&D agreement with Hosp. Garraham
Next 2025
Regulatory approvals Internationalazation
- Product development under GMP in Hosp. Garrhan
- Product development under GMP in Hosp. Garrhan
Our Innovative
Solution
Is An Advanced Therapy Medicinal Product
Combines Allogenic Mesenchymal Stem Cells With Hyaluronic Acid
Our Innovative
Solution
Is An Advanced Therapy Medicinal Product
Combines Allogenic Mesenchymal Stem Cells With Hyaluronic Acid
Our Innovative
Solution
Is An Advanced Therapy Medicinal Product
Combines Allogenic Mesenchymal Stem Cells With Hyaluronic Acid
We Offer
To regenerate the bone naturally
To reduce time to restore bone fuction and mobility
To reduce treatment time with a single intervention
To reduce complications
AI platform to predict treatment outcomes
OUR TEAM
CONICET Researchers | PhDs | BSs in Genetics | Scientific Technological Entrepreneurs
FOUNDERS
Alaniz, Laura
Co-Founder & CEO
Icardi, Antonella
Co-Founder & CEO
Latina, Catalina
Cell Therapy Development
RESEARCH & DEVELOPMENT
Vitale, Daiana
Hyaluronic Acid Specialist
Rosales, Paolo
Inmunology & Biocompatibility
Mantello, Iván
IA & Software Development
ADVISORS
Ferrari, José
Advisor
Chiesa, Gaston
Advisor
García, Mariana
Advisor
Picasso, Ramiro
Advisor
JOIN OUR
MISSION
Our Strategic Partnerships
Our team of investor partners, collaborators and sponsors.
News!
Latest posted updates!
Laura Alaniz was invited to present our current proposal in
Biotechnological development at the «Open Innovation Hackathon 2024». 🎤💡Nuestra CEO Laura Alaniz fue...
Laura Alaniz (CEO ) y Antonella Icardi (CTO) participaron en la 12° edición de la muestra interactiva "TecUNNOBA" (2024), organizada por la UNNOBA.
What are we looking for? To listen and learn from trauma specialists, who shared their clinical experience...
Opportunity to present our company MesencHyal-T to a traumamatology roundtable at La Pequeña Familia clinic.
What are we looking for? To listen and learn from trauma specialists, who shared their clinical experience...
We took part in the "ANMAT Salud 2024 Conference: regulatory member ICH"
We took part in the «ANMAT Salud 2024 Conference: regulatory member ICH» organized by the National Academy...
📢 MesencHyal-T at the III Multidisciplinary Congress of UNNOBA 🎓🔬
MesencHyal-T at the III Multidisciplinary Congress of UNNOBA We are pleased to share that the @MesencHyal-T...
Nuestra CEO Laura Alaniz tuvo el honor de dar una charla sobre emprender y habilidades para el armado de una startup biotecnologica a jóvenes estudiantes
Nuestra CEO Laura Alaniz tuvo el honor de dar una charla sobre emprender y habilidades para el armado...
